Brokerages Set Bausch + Lomb Corporation (NYSE:BLCO) PT at $17.00

Bausch + Lomb Corporation (NYSE:BLCO) has been given an average recommendation of “Hold” by the fifteen ratings firms that are covering the firm, MarketBeat reports. Two research analysts have rated the stock with a sell rating, eight have issued a hold rating and five have assigned a buy rating to the company. The average twelve-month price target among brokerages that have issued ratings on the stock in the last year is $17.00.

BLCO has been the subject of a number of research analyst reports. Royal Bank Of Canada raised their price target on Bausch + Lomb from $17.00 to $19.00 and gave the stock an “outperform” rating in a research note on Friday, November 14th. JPMorgan Chase & Co. increased their target price on Bausch + Lomb from $13.00 to $16.00 and gave the stock a “neutral” rating in a research note on Thursday, October 30th. Barclays boosted their target price on shares of Bausch + Lomb from $16.00 to $17.00 and gave the company an “equal weight” rating in a research note on Friday, October 31st. Raymond James Financial reaffirmed an “outperform” rating and issued a $19.00 price target (up previously from $18.00) on shares of Bausch + Lomb in a research note on Thursday, October 30th. Finally, Wall Street Zen upgraded shares of Bausch + Lomb from a “hold” rating to a “buy” rating in a report on Saturday, November 1st.

Institutional Trading of Bausch + Lomb

A number of large investors have recently modified their holdings of BLCO. Ridgewood Investments LLC bought a new position in Bausch + Lomb in the second quarter worth approximately $26,000. Northwestern Mutual Wealth Management Co. lifted its holdings in shares of Bausch + Lomb by 729.3% in the 2nd quarter. Northwestern Mutual Wealth Management Co. now owns 2,322 shares of the company’s stock worth $30,000 after buying an additional 2,042 shares during the period. Blue Trust Inc. grew its position in shares of Bausch + Lomb by 58.5% during the 2nd quarter. Blue Trust Inc. now owns 4,502 shares of the company’s stock worth $59,000 after buying an additional 1,662 shares in the last quarter. FNY Investment Advisers LLC increased its stake in shares of Bausch + Lomb by 93.8% during the second quarter. FNY Investment Advisers LLC now owns 6,200 shares of the company’s stock valued at $80,000 after buying an additional 3,000 shares during the period. Finally, Jones Financial Companies Lllp raised its holdings in shares of Bausch + Lomb by 55.3% in the third quarter. Jones Financial Companies Lllp now owns 9,112 shares of the company’s stock valued at $132,000 after acquiring an additional 3,246 shares in the last quarter. Hedge funds and other institutional investors own 11.07% of the company’s stock.

Bausch + Lomb Price Performance

Bausch + Lomb stock opened at $16.99 on Friday. Bausch + Lomb has a 12-month low of $10.45 and a 12-month high of $18.55. The company has a current ratio of 1.51, a quick ratio of 0.98 and a debt-to-equity ratio of 0.76. The firm has a 50-day moving average price of $15.96 and a 200-day moving average price of $14.72. The firm has a market capitalization of $6.02 billion, a PE ratio of -19.52, a price-to-earnings-growth ratio of 1.46 and a beta of 0.62.

Bausch + Lomb (NYSE:BLCO) last posted its quarterly earnings data on Wednesday, October 29th. The company reported $0.18 earnings per share for the quarter, topping analysts’ consensus estimates of $0.16 by $0.02. The company had revenue of $1.28 billion for the quarter, compared to analyst estimates of $1.28 billion. Bausch + Lomb had a negative net margin of 6.13% and a positive return on equity of 2.42%. The firm’s revenue for the quarter was up 7.1% on a year-over-year basis. During the same period in the prior year, the company posted $0.13 EPS. As a group, equities research analysts forecast that Bausch + Lomb will post 0.74 EPS for the current year.

Bausch + Lomb Company Profile

Bausch + Lomb Corporation operates as an eye health company in the United States, Puerto Rico, China, France, Japan, Germany, the United Kingdom, Canada, Russia, Spain, Italy, Mexico, Poland, South Korea, and internationally. It operates in three segments: Vision Care, Pharmaceuticals, and Surgical. The Vision Care segment provides contact lens that covers the spectrum of wearing modalities, including daily disposable and frequently replaced contact lenses; and contact lens care products comprising over-the-counter eye drops, eye vitamins, and mineral supplements that address various conditions, such as eye allergies, conjunctivitis, dry eye, and redness relief.